Financial Survey: AngioDynamics (ANGO) vs. Becton, Dickinson and Company (BDX)
Becton, Dickinson and Company (NYSE: BDX) and AngioDynamics (NASDAQ:ANGO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitabiliy, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.
Insider & Institutional Ownership
75.4% of Becton, Dickinson and Company shares are owned by institutional investors. Comparatively, 84.6% of AngioDynamics shares are owned by institutional investors. 1.4% of Becton, Dickinson and Company shares are owned by company insiders. Comparatively, 1.9% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Becton, Dickinson and Company and AngioDynamics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Becton, Dickinson and Company||$12.32 billion||3.47||$3.20 billion||$6.05||33.16|
|AngioDynamics||$356.15 million||1.65||$49.13 million||($0.72)||-22.21|
Becton, Dickinson and Company has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.
This table compares Becton, Dickinson and Company and AngioDynamics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Becton, Dickinson and Company||10.67%||25.37%||7.92%|
This is a breakdown of current ratings and target prices for Becton, Dickinson and Company and AngioDynamics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Becton, Dickinson and Company||1||3||5||1||2.60|
Becton, Dickinson and Company currently has a consensus target price of $188.60, indicating a potential downside of 5.99%. AngioDynamics has a consensus target price of $18.50, indicating a potential upside of 15.70%. Given AngioDynamics’ higher probable upside, analysts plainly believe AngioDynamics is more favorable than Becton, Dickinson and Company.
Becton, Dickinson and Company pays an annual dividend of $2.92 per share and has a dividend yield of 1.5%. AngioDynamics does not pay a dividend. Becton, Dickinson and Company pays out 48.3% of its earnings in the form of a dividend. Becton, Dickinson and Company has raised its dividend for 45 consecutive years.
Risk & Volatility
Becton, Dickinson and Company has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.
Becton, Dickinson and Company beats AngioDynamics on 12 of the 17 factors compared between the two stocks.
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company’s BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.
AngioDynamics Company Profile
AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company’s BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.